Development of medications for the treatment of opiate and cocaine addictions : issues for the government and private sector
Author(s)
Bibliographic Information
Development of medications for the treatment of opiate and cocaine addictions : issues for the government and private sector
National Academy Press, 1995
Available at 3 libraries
  Aomori
  Iwate
  Miyagi
  Akita
  Yamagata
  Fukushima
  Ibaraki
  Tochigi
  Gunma
  Saitama
  Chiba
  Tokyo
  Kanagawa
  Niigata
  Toyama
  Ishikawa
  Fukui
  Yamanashi
  Nagano
  Gifu
  Shizuoka
  Aichi
  Mie
  Shiga
  Kyoto
  Osaka
  Hyogo
  Nara
  Wakayama
  Tottori
  Shimane
  Okayama
  Hiroshima
  Yamaguchi
  Tokushima
  Kagawa
  Ehime
  Kochi
  Fukuoka
  Saga
  Nagasaki
  Kumamoto
  Oita
  Miyazaki
  Kagoshima
  Okinawa
  Korea
  China
  Thailand
  United Kingdom
  Germany
  Switzerland
  France
  Belgium
  Netherlands
  Sweden
  Norway
  United States of America
Note
Committee chairman: Laurence E. Earley
Support for this study was provided by the National Institute on Drug Abuse
Includes bibliographical references
Description and Table of Contents
Description
Pharmacotherapy, as a means of treating drug addiction in combination with other treatment modalities, has received too little attention from the research community, the pharmaceutical industry, public health officials, and the federal government. Medications to combat drug addiction could have an enormous impact on the medical consequences and socioeconomic problems associated with drug abuse, both for drug-dependent individuals and for American society as a whole. This book examines the current environment for and obstacles to the development of anti-addiction medications, specifically those for treating opiate and cocaine addictions, and proposes incentives for the pharmaceutical industry that would help overcome those obstacles and accelerate the development of anti-addiction medications.
Table of Contents
Front Matter
Executive Summary
1 Introduction
2 Overview of the State of Scientific Knowledge Concerning Drug
Addiction
3 Assessment of the Medications Development Division
4 Treatment Setting and Effectiveness
5 Treatment Financing and Trends in Health Insurance
6 Training and Education
7 Federal Laws and Regulations
8 State Laws and Regulations
9 Market Obstacles and Creating Incentives
Appendix A: Acknowledgments
Appendix B: Organization and Mission Statements of NIDA's
Medications Development Division and Its Branches
Appendix C: Diagnostic Criteria for Psychoactive Substance
Dependence
Appendix D: Survey of Pharmaceutical Companies
Appendix E: Model Federal Programs in Pharmaceutical R&D
Appendix F: Workshop Agenda and Participants
Appendix G: Health Care Reform Legislation
Appendix H: Acronyms
Table of Contents
- 1 Front Matter
- 2 Executive Summary
- 3 1 Introduction
- 4 2 Overview of the State of Scientific Knowledge Concerning Drug Addiction
- 5 3 Assessment of the Medications Development Division
- 6 4 Treatment Setting and Effectiveness
- 7 5 Treatment Financing and Trends in Health Insurance
- 8 6 Training and Education
- 9 7 Federal Laws and Regulations
- 10 8 State Laws and Regulations
- 11 9 Market Obstacles and Creating Incentives
- 12 Appendix A: Acknowledgments
- 13 Appendix B: Organization and Mission Statements of NIDA's Medications Development Division and Its Branches
- 14 Appendix C: Diagnostic Criteria for Psychoactive Substance Dependence
- 15 Appendix D: Survey of Pharmaceutical Companies
- 16 Appendix E: Model Federal Programs in Pharmaceutical R 17 Appendix F: Workshop Agenda and Participants
- 18 Appendix G: Health Care Reform Legislation
- 19 Appendix H: Acronyms
by "Nielsen BookData"